Impact of canagliflozin combined with metformin therapy on reducing cardiovascular risk in type 2 diabetes patients

Table 5 Comparison of the incidence of serious adverse reactions between the two groups

Characteristic (number, %)	Control group(n = 116)	Observation group(n = 116)	χ²	P
Serious adverse reactions	14(12.07)	11(9.48)	0.404	0.525
Hypoglycemia	3(2.59)	4(3.45)	0.147	0.701
Diabetic ketoacidosis	2(1.72)	1(0.86)	0.338	0.561
Adverse reactions related to osmotic diuresis	1(0.86)	0(0.00)	1.004	0.316
Urinary tract infection	4(3.45)	5(4.31)	0.116	0.734
male	1(0.86)	2(1.72)
female	3(2.59)	3(2.59)
Gastrointestinal related adverse reactions	3(2.59)	1(0.86)	1.018	0.313
Adverse liver events	1(0.86)	0(0.00)	1.004	0.316

Note: Hypoglycemia includes biochemical episodes (fingerstick or blood glucose ≤ 3.9 mmol/L), with or without symptoms, as well as severe episodes (requiring assistance from another person or leading to seizures, loss of consciousness, or cognitive dysfunction). Adverse reactions associated with osmotic diuresis include dry mouth, polyuria, polydipsia, and cystitis. Gastrointestinal adverse reactions include diarrhea, nausea, and vomiting. Liver adverse events include acute liver failure or the need for liver transplantation

ISSN: 1758-5996